{"id":496757,"date":"2020-07-17T13:48:01","date_gmt":"2020-07-17T13:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496757"},"modified":"2020-07-17T13:48:01","modified_gmt":"2020-07-17T13:48:01","slug":"peripheral-tcell-lymphoma-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-tcell-lymphoma-epidemiology-forecast-till-2030_496757.html","title":{"rendered":"Peripheral T-Cell Lymphoma Epidemiology Forecast till 2030"},"content":{"rendered":"
\"Peripheral<\/a><\/p>\n
\n
DelveInsight<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Peripheral T-Cell Lymphoma (PTCL) Epidemiology Forecast\u20132030\u2019 report delivers an in-depth understanding of the disease, historical and forecasted PTCL epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/div>\n

Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer (NK) cells.<\/p>\n

 <\/p>\n

Key Highlights from<\/span><\/span> <\/span>Peripheral T-Cell Lymphoma <\/span><\/a>report<\/a>:-<\/span><\/span><\/span><\/p>\n

·         <\/span><\/span>PTCL accounts for 10–15% of all non-Hodgkin lymphomas worldwide.<\/p>\n

·         <\/span><\/span>The total incident population of Peripheral T-Cell Lymphoma (PTCL) in 7MM in 2017- 16,298<\/p>\n

·         <\/span><\/span>The incident population of PTCL in 2017<\/p>\n

Ø  <\/span><\/span>The United States – 6,110<\/p>\n

Ø  <\/span><\/span>Germany – 1,183<\/p>\n

 <\/p>\n

Ø  <\/span><\/span>UK – 1,100 <\/p>\n

·         <\/span><\/span>PTCL is categorized into four stages based on the area affected and incident cases in the United States in 2017:-<\/p>\n

Ø  <\/span><\/span>Stage I – 876<\/p>\n

Ø  <\/span><\/span>Stage II – 727<\/p>\n

Ø  <\/span><\/span>Stage III – 1,434<\/p>\n

Ø  <\/span><\/span>Stage IV  – 3,074<\/p>\n

·         <\/span><\/span>The incident cases of PTCL in the United States in year 2017<\/p>\n

Ø  <\/span><\/span>PTCL-Not-Otherwise Specified (PTCL-NOS) accounts for 31% of all incident cases of PTCL<\/p>\n

 <\/p>\n

Ø  <\/span><\/span>Anaplastic Large Cell Lymphoma (ALCL) accounts for 26% of all incident cases of PTCL<\/p>\n

 <\/p>\n

Scope of the Report:-<\/strong><\/p>\n

 The report covers the descriptive overview of PTCL, explaining its causes, signs and symptoms, and pathophysiology.<\/p>\n

 The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.<\/p>\n

 The report assesses the disease risk and burden.<\/p>\n

 The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of PTCL, Stage-specific Incident Cases of PTCL, and Subtype-specific Incident Cases of PTCL.<\/p>\n

 <\/p>\n

Request for sample pages<\/a><\/p>\n

 <\/p>\n

Table of contents <\/p>\n

1. Key Insights<\/p>\n

 <\/p>\n

2. Executive Summary of Peripheral T-cell Lymphoma (PTCL)<\/p>\n

 <\/p>\n

3. Disease Background and Overview: Peripheral T-cell Lymphoma (PTCL)<\/p>\n

 <\/p>\n

3.1. Introduction<\/p>\n

 <\/p>\n

3.2. Classification of PTCL<\/p>\n

 <\/p>\n

3.2.1. WHO Classification System<\/p>\n

 <\/p>\n

3.3. Subtypes of PTCL<\/p>\n

 <\/p>\n

3.3.1. Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)<\/p>\n

 <\/p>\n

3.3.2. Anaplastic Large Cell Lymphoma (ALCL)<\/p>\n

 <\/p>\n

3.3.3. Angioimmunoblastic T-Cell Lymphoma (AITL)<\/p>\n

 <\/p>\n

3.4. Signs and Symptoms<\/p>\n

 <\/p>\n

3.5. Cause of PTCL<\/p>\n

 <\/p>\n

3.6. Pathophysiology<\/p>\n

 <\/p>\n

3.7. Other conditions that can mimic PTCL<\/p>\n

 <\/p>\n

3.8. Staging<\/p>\n

 <\/p>\n

3.9. Diagnosis<\/p>\n

 <\/p>\n

3.9.1. Blood tests<\/p>\n

 <\/p>\n

3.9.2. Diagnostic Scans<\/p>\n

 <\/p>\n

4. PTCL Epidemiology and Patient Population<\/p>\n

 <\/p>\n

4.1. Key Findings<\/p>\n

 <\/p>\n

4.2. KOL Views<\/p>\n

 <\/p>\n

4.3. PTCL Epidemiology Methodology<\/p>\n

 <\/p>\n

4.4. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM<\/p>\n

 <\/p>\n

5. United States Epidemiology<\/p>\n

 <\/p>\n

5.1. Assumptions and Rationale<\/p>\n

 <\/p>\n

5.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States<\/p>\n

 <\/p>\n

5.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States<\/p>\n

 <\/p>\n

5.4. Subtype-specific Incident cases of Peripheral T-cell Lymphoma (PTCL) in the United States<\/p>\n

 <\/p>\n

6. EU5 Epidemiology<\/p>\n

 <\/p>\n

6.1. Assumptions and Rationale<\/p>\n

 <\/p>\n

6.2. Germany Epidemiology<\/p>\n

 <\/p>\n

6.2.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany<\/p>\n

 <\/p>\n

6.2.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany<\/p>\n

 <\/p>\n

6.2.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany<\/p>\n

 <\/p>\n

6.3. France Epidemiology<\/p>\n

 <\/p>\n

6.3.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France<\/p>\n

 <\/p>\n

6.3.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France<\/p>\n

 <\/p>\n

6.3.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France<\/p>\n

 <\/p>\n

6.4. Italy Epidemiology<\/p>\n

 <\/p>\n

6.4.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy<\/p>\n

 <\/p>\n

6.4.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy<\/p>\n

 <\/p>\n

6.4.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy<\/p>\n

 <\/p>\n

6.5.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain<\/p>\n

 <\/p>\n

6.5.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain<\/p>\n

 <\/p>\n

6.5.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain<\/p>\n

 <\/p>\n

6.6. United Kingdom Epidemiology<\/p>\n

 <\/p>\n

6.6.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK<\/p>\n

 <\/p>\n

6.6.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK<\/p>\n

 <\/p>\n

6.6.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK<\/p>\n

 <\/p>\n

7. Japan Epidemiology<\/p>\n

 <\/p>\n

7 .1. Assumptions and Rationale<\/p>\n

 <\/p>\n

7.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan<\/p>\n

 <\/p>\n

7.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan<\/p>\n

 <\/p>\n

7.4. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan<\/p>\n

 <\/p>\n

8. Recognized Establishments<\/p>\n

 <\/p>\n

9. Appendix<\/p>\n

 <\/p>\n

9.1. Bibliography<\/p>\n

 <\/p>\n

9.2. PTCL Report Methodology<\/p>\n

 <\/p>\n

10. DelveInsight Capabilities<\/p>\n

 <\/p>\n

11. Disclaimer<\/p>\n

 <\/p>\n

12. About DelveInsight<\/p>\n

 <\/p>\n

·         <\/span><\/span><\/span>Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer (NK) cells.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight DelveInsight\u2019s \u2018Peripheral T-Cell Lymphoma (PTCL) Epidemiology Forecast\u20132030\u2019 report delivers an in-depth understanding of the disease, historical and forecasted PTCL epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. Peripheral T-Cell Lymphoma (PTCL) is … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-496757","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496757"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496757\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}